Cullen O'GOrman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cullen O'GOrman has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Nicola Warren
The University of Queensland
6 shared publications Charles Kassardjian
Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
4 shared publications- Dan Siskind
Queensland Centre for Mental Health Research, Wacol, Australia
4 shared publications - Simon A. Broadley
School of Medicine and Dentistry, Griffith University, Gold Coast, Qld, Australia
3 shared publications - Andrea J. Boon
Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, U.S.A.
2 shared publications Andrew Swayne
Faculty of Medicine, The University of Queensland, Brisbane, Australia
2 shared publications
Latest Publications
- Open Access
- 6 November 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 53, 101237
A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study
- 6 November 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 53, 101237
Open AccessA contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study
- 30 May 2020
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 142 (1) , 52-57
Evaluation of the proposed anti‐N‐methyl‐d‐aspartate receptor encephalitis clinical diagnostic criteria in psychiatric patients
Objective The gold standard for diagnosing anti‐NMDAR encephalitis is demonstration of the antibody in CSF. Clinical diagnostic criteria have been proposed for when this is not available in a timely manner which is evaluated, in this study, for a psychiatric population. Methods This study retrospectively assessed the proposed criteria in patients presenting to psychiatric services for the first time with known anti‐NMDAR antibody status. Antibody positive cases were derived from the literature (conception to December 2019) and a state wide (Queensland, Australia) cohort. Antibody negative cases were derived from a service wide (Metro South, Queensland, Australia) cohort of psychiatric cases which underwent antibody testing for routine organic screening. Sensitivity and specificity were calculated at 1 week following admission and the point of discharge. Results The proposed criteria were applied to 641 cases (500 antibody positive, 141 antibody negative), demonstrating a sensitivity which increased from around 19% after 1 week to 49% by the point of discharge. Specificity was 100% at both time points. The mean average time to become positive using the proposed criteria was 19.5 days compared to 34.9 days for return of antibody testing. Conclusions High specificity of the proposed criteria, seen in this study, suggests that cases which are positive can be considered for expedited commencement of treatment. However, if clinical suspicion is high despite criteria being negative, it is essential to test CSF for anti‐NMDA antibody.
- 30 May 2020
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 142 (1) , 52-57
Evaluation of the proposed anti‐N‐methyl‐d‐aspartate receptor encephalitis clinical diagnostic criteria in psychiatric patients
Objective The gold standard for diagnosing anti‐NMDAR encephalitis is demonstration of the antibody in CSF. Clinical diagnostic criteria have been proposed for when this is not available in a timely manner which is evaluated, in this study, for a psychiatric population. Methods This study retrospectively assessed the proposed criteria in patients presenting to psychiatric services for the first time with known anti‐NMDAR antibody status. Antibody positive cases were derived from the literature (conception to December 2019) and a state wide (Queensland, Australia) cohort. Antibody negative cases were derived from a service wide (Metro South, Queensland, Australia) cohort of psychiatric cases which underwent antibody testing for routine organic screening. Sensitivity and specificity were calculated at 1 week following admission and the point of discharge. Results The proposed criteria were applied to 641 cases (500 antibody positive, 141 antibody negative), demonstrating a sensitivity which increased from around 19% after 1 week to 49% by the point of discharge. Specificity was 100% at both time points. The mean average time to become positive using the proposed criteria was 19.5 days compared to 34.9 days for return of antibody testing. Conclusions High specificity of the proposed criteria, seen in this study, suggests that cases which are positive can be considered for expedited commencement of treatment. However, if clinical suspicion is high despite criteria being negative, it is essential to test CSF for anti‐NMDA antibody.
- 19 November 2019
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (3) , 435-440
Psychiatric management of anti-NMDAR encephalitis: a cohort analysis
Background: Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is an immune-mediated disorder which requires multi-disciplinary treatment including immunomodulation therapy. First presentation is most commonly to psychiatric services and continuing psychiatric care is required to treat disabling symptoms, such as behaviour disturbance, psychosis and catatonia. There is minimal available evidence to guide symptomatic treatment and concern for increased sensitivity to antipsychotics complicates traditional approaches.Methods: All cases of cerebrospinal fluid positive anti-NMDAR encephalitis tested in Queensland, Australia were identified. Demographic, clinical and therapeutic data were collected and reviewed by two independent clinicians. Pre-specified variables reflecting possible treatment side effects were compared.Results: The majority of the 30 cases (83%) had early psychiatric symptoms and were treated with antipsychotics (67%), average daily olanzapine equivalence dose of 11.5 mg, prior to immunomodulation therapy. Although there was an 88% reduction in cases with aggression, there was little improvement in psychosis, affective symptoms or catatonia with antipsychotics alone. In the cases with psychiatric symptoms, there was no significant difference in the rate of occurrence of neurological and autonomic symptoms between cases prescribed and not prescribed antipsychotics.Conclusions: Psychiatric input is imperative for both acute and longer-term management of anti-NMDAR encephalitis. Primary symptomatic treatment should remain immunotherapy and surgery. Antipsychotic medications have particular value in managing agitation and aggression. Potential side effects from antipsychotic treatment are difficult to differentiate from progression of anti-NMDAR encephalitis but there was no evidence in this cohort of increased antipsychotic sensitivity. Treatment with psychotropic medication should be individualised and adjusted during the course of the illness.
- 19 November 2019
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (3) , 435-440
Psychiatric management of anti-NMDAR encephalitis: a cohort analysis
Background: Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is an immune-mediated disorder which requires multi-disciplinary treatment including immunomodulation therapy. First presentation is most commonly to psychiatric services and continuing psychiatric care is required to treat disabling symptoms, such as behaviour disturbance, psychosis and catatonia. There is minimal available evidence to guide symptomatic treatment and concern for increased sensitivity to antipsychotics complicates traditional approaches.Methods: All cases of cerebrospinal fluid positive anti-NMDAR encephalitis tested in Queensland, Australia were identified. Demographic, clinical and therapeutic data were collected and reviewed by two independent clinicians. Pre-specified variables reflecting possible treatment side effects were compared.Results: The majority of the 30 cases (83%) had early psychiatric symptoms and were treated with antipsychotics (67%), average daily olanzapine equivalence dose of 11.5 mg, prior to immunomodulation therapy. Although there was an 88% reduction in cases with aggression, there was little improvement in psychosis, affective symptoms or catatonia with antipsychotics alone. In the cases with psychiatric symptoms, there was no significant difference in the rate of occurrence of neurological and autonomic symptoms between cases prescribed and not prescribed antipsychotics.Conclusions: Psychiatric input is imperative for both acute and longer-term management of anti-NMDAR encephalitis. Primary symptomatic treatment should remain immunotherapy and surgery. Antipsychotic medications have particular value in managing agitation and aggression. Potential side effects from antipsychotic treatment are difficult to differentiate from progression of anti-NMDAR encephalitis but there was no evidence in this cohort of increased antipsychotic sensitivity. Treatment with psychotropic medication should be individualised and adjusted during the course of the illness.
- 1 March 2019
- Published by Elsevier in Brain Stimulation
- Vol. 12 (2) , 329-334
Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases
- 1 March 2019
- Published by Elsevier in Brain Stimulation
- Vol. 12 (2) , 329-334
Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases
- 1 February 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 65, 20-24
EEG findings in NMDA encephalitis – A systematic review
- 1 February 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 65, 20-24
EEG findings in NMDA encephalitis – A systematic review
- 22 August 2018
- Published by Wiley in Muscle & Nerve
- Vol. 58 (5) , 726-729
Musculocutaneous neuropathy
Introduction: Isolated musculocutaneous neuropathy is uncommon. In this study we aimed to determine its causes and clinical presentation and interpret the electrodiagnostic findings associated with this condition. Methods: Our investigation was a retrospective review of patients diagnosed with musculocutaneous neuropathy at the Mayo Clinic (Rochester, Minnesota) electromyography (EMG) laboratory between 1997 and 2015. Results: Thirty‐two patients with musculocutaneous neuropathy and 5 patients with lateral antebrachial cutaneous neuropathy were identified. The most common cause was acute trauma or surgery (65%). Fourteen percent of the cases were idiopathic and 14% were inflammatory. Pain and sensory disturbance were more common presentations than weakness. Weakness from nerve injury was not noted in 2 patients, suggesting that other muscles may provide adequate elbow flexion/supination. The bilateral absence of lateral antebrachial cutaneous nerve sensory responses suggests an inflammatory cause. Discussion: Musculocutaneous neuropathy usually results from trauma or iatrogenic injury. Nerve conduction studies alone are insufficient to confirm neuropathy, and needle EMG examination should be a routine part of the diagnostic evaluation. Muscle Nerve 58: 726–729, 2018
- 22 August 2018
- Published by Wiley in Muscle & Nerve
- Vol. 58 (5) , 726-729
Musculocutaneous neuropathy
Introduction: Isolated musculocutaneous neuropathy is uncommon. In this study we aimed to determine its causes and clinical presentation and interpret the electrodiagnostic findings associated with this condition. Methods: Our investigation was a retrospective review of patients diagnosed with musculocutaneous neuropathy at the Mayo Clinic (Rochester, Minnesota) electromyography (EMG) laboratory between 1997 and 2015. Results: Thirty‐two patients with musculocutaneous neuropathy and 5 patients with lateral antebrachial cutaneous neuropathy were identified. The most common cause was acute trauma or surgery (65%). Fourteen percent of the cases were idiopathic and 14% were inflammatory. Pain and sensory disturbance were more common presentations than weakness. Weakness from nerve injury was not noted in 2 patients, suggesting that other muscles may provide adequate elbow flexion/supination. The bilateral absence of lateral antebrachial cutaneous nerve sensory responses suggests an inflammatory cause. Discussion: Musculocutaneous neuropathy usually results from trauma or iatrogenic injury. Nerve conduction studies alone are insufficient to confirm neuropathy, and needle EMG examination should be a routine part of the diagnostic evaluation. Muscle Nerve 58: 726–729, 2018
- 3 August 2018
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 25 (5) , 750-753
A case of immune-mediated encephalitis related to daclizumab therapy
This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over 12 cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, cerebrospinal fluid (CSF) examination and brain biopsy.
- 3 August 2018
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 25 (5) , 750-753
A case of immune-mediated encephalitis related to daclizumab therapy
This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over 12 cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, cerebrospinal fluid (CSF) examination and brain biopsy.
- 10 July 2018
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 138 (5) , 401-408
Refining the psychiatric syndrome of anti‐N‐methyl‐d‐aspartate receptor encephalitis
Objective: To review the psychiatric symptoms of anti‐N‐methyl‐d‐aspartate (NMDA) receptor encephalitis, in an attempt to differentiate the presentation from a primary psychiatric disorder.Method: A systematic literature review of PubMed and EMBASE of all published cases of anti‐NMDA receptor encephalitis was performed from inception to January 2018.Results: There were 706 cases of anti‐NMDA receptor encephalitis identified. Cases were typically young (mean age 22.6 years, SD 14.8), female (F : M ratio 3.5 : 1) and presented with significant behavioural disturbance. Reported behaviour was most commonly severe agitation and aggression, abnormal speech, and catatonia. Psychosis occurred in 45.8% of cases. Investigation results were inconsistent (MRI abnormal in 35.6%, EEG abnormal in 83.0%) and non‐specific. Psychiatric treatment often required multiple psychotropics, and there may be increased risk of significant side‐effects such as neuroleptic malignant syndrome. Prognosis was usually good; however, cognitive and behavioral symptoms remained prominent during recovery, and psychiatrist involvement was required in this period.Conclusion: The presentation of anti‐NMDA receptor encephalitis is variable. However, there are often psychiatric features which are atypical to a primary psychiatric illness, such as severe agitation, speech abnormalities, and catatonia, which may help early identification.
- 10 July 2018
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 138 (5) , 401-408
Refining the psychiatric syndrome of anti‐N‐methyl‐d‐aspartate receptor encephalitis
Objective: To review the psychiatric symptoms of anti‐N‐methyl‐d‐aspartate (NMDA) receptor encephalitis, in an attempt to differentiate the presentation from a primary psychiatric disorder.Method: A systematic literature review of PubMed and EMBASE of all published cases of anti‐NMDA receptor encephalitis was performed from inception to January 2018.Results: There were 706 cases of anti‐NMDA receptor encephalitis identified. Cases were typically young (mean age 22.6 years, SD 14.8), female (F : M ratio 3.5 : 1) and presented with significant behavioural disturbance. Reported behaviour was most commonly severe agitation and aggression, abnormal speech, and catatonia. Psychosis occurred in 45.8% of cases. Investigation results were inconsistent (MRI abnormal in 35.6%, EEG abnormal in 83.0%) and non‐specific. Psychiatric treatment often required multiple psychotropics, and there may be increased risk of significant side‐effects such as neuroleptic malignant syndrome. Prognosis was usually good; however, cognitive and behavioral symptoms remained prominent during recovery, and psychiatrist involvement was required in this period.Conclusion: The presentation of anti‐NMDA receptor encephalitis is variable. However, there are often psychiatric features which are atypical to a primary psychiatric illness, such as severe agitation, speech abnormalities, and catatonia, which may help early identification.
- Open Access
- 14 November 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 89 (20) , e245
Teaching Video Neuro Images : The pathologic deep abdominal reflex
- 14 November 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 89 (20) , e245
Open AccessTeaching Video Neuro Images : The pathologic deep abdominal reflex
- 10 October 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (12) , 1060-1064
Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Objectives Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson’s disease, characterised by addictive behaviour and excessive use of dopaminergic medication. DDS may frequently go unrecognised or misdiagnosed. We aimed to clarify current understanding of presentation, risk factors, comorbidities and management of DDS. Methods Case reports were identified through a systematic search of databases (PubMed, Embase) with the following terms: dopaminergic dysregulation syndrome, hedonistic homeostatic dysregulation, dopamine/levodopa addiction. Results We reviewed 390 articles, identifying 98 cases of DDS. Early-onset Parkinson’s disease (67%) and male gender (83%) were common. DDS presented with significant physical and social impairment, actions to enable or prevent detection of overuse, as well as mood, anxiety and motor fluctuations. All DDS cases met DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) substance use disorder criteria. Past substance and psychiatric history was present in 15.3% and 10.2% of cases. Comorbid impulse control disorders (61%), psychosis (32%) and panic attacks (14%) were common. A large variety of management strategies were used; only 56% of cases resolving. Sodium valproate was successful in 5/5 cases. The response to deep brain stimulation varied. Conclusions Given the functional impairment, medical and psychiatric consequences and the difficulties of treatment, early identification of DDS should be a priority.
- 10 October 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (12) , 1060-1064
Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Objectives Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson’s disease, characterised by addictive behaviour and excessive use of dopaminergic medication. DDS may frequently go unrecognised or misdiagnosed. We aimed to clarify current understanding of presentation, risk factors, comorbidities and management of DDS. Methods Case reports were identified through a systematic search of databases (PubMed, Embase) with the following terms: dopaminergic dysregulation syndrome, hedonistic homeostatic dysregulation, dopamine/levodopa addiction. Results We reviewed 390 articles, identifying 98 cases of DDS. Early-onset Parkinson’s disease (67%) and male gender (83%) were common. DDS presented with significant physical and social impairment, actions to enable or prevent detection of overuse, as well as mood, anxiety and motor fluctuations. All DDS cases met DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) substance use disorder criteria. Past substance and psychiatric history was present in 15.3% and 10.2% of cases. Comorbid impulse control disorders (61%), psychosis (32%) and panic attacks (14%) were common. A large variety of management strategies were used; only 56% of cases resolving. Sodium valproate was successful in 5/5 cases. The response to deep brain stimulation varied. Conclusions Given the functional impairment, medical and psychiatric consequences and the difficulties of treatment, early identification of DDS should be a priority.